Analysis of HCV RNA persistent positive results and influencing factors in reported Hepatitis C cases from two counties of Nanchang, 2004-2022

doi:10.19871/j.cnki.xfcrbzz.2025.01.003

Abstract

Abstract: Objective To understand the current infection status of reported hepatitis C (HCV) confirmed cases in two counties Nanchang from 2004 to 2022, and to analyze the factors related to the persistence of HCV RNA positivity and to provide scientific basis for the elimination of hepatitis C. Method A cluster sampling method was used to select two districts with the highest number of previously reported HCV cases from nine counties/districts in Nanchang as study sites. Data on HCV confirmed cases from 2004 to 2022 were downloaded from the Chinese Center for Disease Control and Prevention Information System. After a thorough review and organization of the database, on-site questionnaire surveys were conducted to analyze the current status of antiviral treatment. Logistic regression analysis was used to identify factors associated with persistent HCV RNA positivity. Result A total of 510 previously confirmed HCV cases were surveyed, with 505 valid questionnaires (99.02%) returned. The rate of persistent HCV RNA positivity was 30.89%, and the rate of antiviral treatment was 24.55%. Multivariate logistic regression analysis showed that male gender (OR=2.041,95%CI:1.332-3.127) personal monthly income <3000 yuan (OR=2.121,95%CI:1.358-3.312) and comorbid diabetes (OR=2.246,95%CI:1.153-4.377) were risk factors for persistent HCV RNA positivity. While awareness of hepatitis C knowledge (OR=0.384,95%CI:0.249-0.592) and having received antiviral treatment (OR=0.186,95%CI:0.101-0.342) were protective factors. The cure rate of direct-acting antivirals (DAAs) treatment regimen was higher than that of interferon (IFN) combined with ribavirin treatment regimen(χ ²=11.246,P=0.004). Conclusion The rate of persistent HCV RNA positivity among previously reported HCV cases from two counties of Nanchang remains high. It is imperative to enhance health education on hepatitis C prevention, expand treatment coverage, and ultimately aim for the elimination of hepatitis C as a public health threat.

Key words: Hepatitis C, Hepatitis C virus RNA, Antiviral treatment, Influencing factors

CLC Number:

R512.6

Tu Zhibin, Lu Liang, Quan Kaifeng, Zhou Yalan, Kuang Jie, Zhou Xianfeng, Feng Changhua, Qiu Liping, Tong Xiaoqin, Mo Jiali. Analysis of HCV RNA persistent positive results and influencing factors in reported Hepatitis C cases from two counties of Nanchang, 2004-2022[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(1): 12-16.

References

[1] MARTINELLO M, SOLOMON SS, TERRAULT NA, et al.Hepatitis C[J].Lancet, 2023, 402(10407):1085-1096.
[2] 崔富强,林炳亮,刘志华,等.中国消除病毒性肝炎公共卫生危害的进展[J].中国病毒病杂志, 2023, 13(5):327-336.
[3] 谢骊, 蔡雷鸣, 冯颖, 等. 丙型病毒性肝炎抗体检测与HCV高敏核酸检测对病毒性丙型肝炎的筛查价值研究[J].标记免疫分析与临床, 2024, 31(3):456-459, 467.
[4] 戴倩梅, 丁体龙, 代雪枫, 等.高敏丙型肝炎病毒核糖核酸在丙型肝炎中的诊断价值[J].检验医学与临床,2024,21(4):487-490.
[5] 国家卫生健康委办公厅,科技部办公厅,工业和信息化部办公厅,等. 消除丙型肝炎公共卫生危害行动工作方案(2021—2030年)[EB/OL].[2022-12-20].https://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml.
[6] 中华人民共和国国家卫生和计划生育委员会.WS 213—2018丙型肝炎诊断[J].中国病毒病杂志, 2018, 8(4):248-251.
[7] 中国疾病预防控制中心艾防中心.关于开展全国丙肝知识知晓率调查工作的通知(中疾控艾发〔2021〕14号)[Z].(2021-05-14).
[8] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019年版)[J].中国病毒病杂志, 2020, 10(1):26-46.
[9] 张钏沨, 张培栋, 孙传武, 等.2004-2020年徐州市既往丙型肝炎患者抗病毒治疗情况及影响因素分析[J].中国艾滋病性病, 2022, 28(12):1355-1358.
[10] 杨雨晴, 张琬悦, 刘春桃, 等. 云南省部分医疗机构就诊者丙型病毒性肝炎防治知识知晓情况分析[J].中国艾滋病性病, 2023, 29(4):462-463.
[11] 饶展宏, 孙群露, 涂玉山, 等. 深圳市宝安区565例丙型肝炎确诊病例抗病毒治疗情况及其影响因素[J].中国艾滋病性病, 2020, 26(7):749-752.
[12] 李宁, 刘露, 姬晓宇, 等. 河南省2004-2021年报告丙型肝炎病例感染现状分析[J].中国艾滋病性病, 2024, 30(7):683-687.
[13] 樊紫娟. 基于患者满意度的公立医院医疗服务质量提升研究[D].乌鲁木齐:新疆农业大学, 2022.
[14] ZIED HY, ABO ALNASR NM, EL-BENDARY AS, et al.Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4[J].Diabetes Metab Syndr, 2020, 14(4):679-682.
[15] 张心怡, 贺娜, 张粉娜, 等. 丙型肝炎病毒感染合并2型糖尿病的相关研究进展[J].肝脏, 2024, 29(3):355-357.
[16] 孟琴, 刘玄华, 蓝光华. 我国不同人群丙型肝炎防治知识知晓现状[J].应用预防医学, 2023, 29(4):297-300.
[17] 虞接军, 徐朋, 刘鹏程, 等. 丙型病毒性肝炎患者疾病防治知识知晓情况及相关因素[J].中华疾病控制杂志, 2023, 27(7):745-750.
[18] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J].中华传染病杂志, 2023, 41(1):29-46.
[19] WORLD HEALTH ORGANIZATION. Global hepatitis report2024: action for access in low- and middle-income countries,2024[EB/OL].[2024-04-09].https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-c.
[20] 李晓月, 李述捷, 易永祥. 乙型肝炎病毒和丙型肝炎病毒相关性肝癌的研究进展[J/CD].新发传染病电子杂志, 2022, 7(1):92-99.